News
Video
Author(s):
Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.
Long-Term Data Support Continued Use of Brexu-Cel in R/R Mantle Cell Lymphoma
FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma
Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma
Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD
NDI-101150 Demonstrates Antitumor Activity, Safety in Heavily Pretreated RCC
Revisit Every OncLive On Air Episode From November 2024
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma
Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS